Development of the Swedish anticholinergic burden scale (Swe-ABS).

ABSTRACT:

Background

Drugs with anticholinergic properties are associated with cognitive adverse effects, especially in patients vulnerable to central muscarinic antagonism. A variety of drugs show weak, moderate or strong anticholinergic effects. Therefore, the cumulative anticholinergic burden should be considered in patients with cognitive impairment. This study aimed to develop a Swedish Anticholinergic Burden Scale (Swe-ABS) to be used in health care and research.

Methods

A systematic literature review was conducted in PubMed and Ovid Embase to identify previously published tools quantifying anticholinergic drug burden (i.e., exposure). Drugs and grading scores (0-3, no to high anticholinergic activity) were extracted from identified lists. Enteral and parenteral drugs authorized

SUBMITTER: Rube T 

PROVIDER: S-EPMC10464171 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature